Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.63 |
| ▸ | CTSK | P43235 | 6/20 | 0.63 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200553 | 0.93 | CTSS (0.73) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL4200549 | 0.93 | CTSS (0.73) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL5552352 | 0.90 | CTSS (0.55) | CTSSCTSKCTSBCTSLLMNA | |
| SCHEMBL29527526 | 0.90 | CTSS (0.73) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL3767022 | 0.86 | CTSS (0.63) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL5557488 | 0.84 | CTSS (0.52) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL11481763 | 0.84 | CTSS (0.57) | CTSSCTSKCTSLATMGAA | |
| SCHEMBL1752677 | 0.83 | CTSK (0.60) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL3759870 | 0.82 | CTSK (0.56) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL27158950 | 0.82 | CTSK (0.56) | CTSSCTSKCTSBCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | CTSS 596/4885CTSK 306/4885CTSB 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.